



**Supplementary Figure S1.** Bar chart representing the functionally enriched gene ontology terms associated with resistance to alpelisib (AR) and alpelisib + trastuzumab (ATR) in HER2+/PIK3CA mutant breast cancer cell lines.


- Gene ontology enrichment in KPL4 AR versus KPL4 treated with alpelisib for 48 hours**



- Gene ontology enrichment in KPL4 ATR versus KPL4 treated with alpelisib plus trastuzumab for 48 hours



- Gene ontology enrichment in HCC1954 AR versus Hcc1954 treated with alpelisib for 48 hours



- Gene ontology enrichment in HCC1954 ATR versus HCC1954 treated with alpelisib plus trastuzumab for 48 hours

